Dopavision GmbH is a pre-clinical stage company developing a digital therapeutic using a VR headset that aims to slow down myopia progression via the local action of dopamine, for children at the age of 5 to 14 years. The therapeutic product named “MyopiaX®” is based on the finding that the light stimulation (with a specific wavelength) of certain non-visual nerve cells in the blind spot activates the local release of neurotransmitters that have an effect on the slowdown of myopia progression.